The purpose of the trial is to see whether giving tranexamic acid during surgery changes the rate of post‑operative infections within one year. After the procedure, participants are followed for up to twelve months with check‑ups at two weeks, three months and one year. During these visits doctors look at how the wound is healing, whether the skin has opened up (wound dehiscence), how much blood loss occurred by measuring blood‑type protein levels, and if any additional surgery is needed. Bone healing (fusion) is checked at the final visit using a special imaging test called computed tomography, which produces detailed pictures of the bones. All participants receive the same standard care apart from the study medication, and the study records any infections, wound problems, extra surgeries, and the overall success of the bone fusion.

The purpose of the study is to assess the safety and effectiveness of this stem cell treatment compared to a placebo. Participants in the study will receive an injection into their knee joint, either with the stem cell treatment or a placebo. The study will monitor knee symptoms and any side effects over a period of time to determine how well the treatment works and how safe it is for patients.

Throughout the study, participants will be asked to keep a diary of their knee pain and other symptoms. They will also undergo various assessments, including the Knee Injury and Osteoarthritis Score (KOOS) and MRI scans, to evaluate changes in their knee condition. The study aims to provide valuable insights into the potential benefits of using stem cells for treating knee osteoarthritis.

Participants will take the assigned drug pair for several months while continuing usual care. During the study they will have regular visits for blood and urine samples, simple pain questionnaires, and brief physical checks. The laboratory work will look at levels of inflammation‑related proteins and cytokines to understand any changes, and safety will be monitored by recording any unwanted effects or abnormal test results. The overall goal is to determine whether the drug combinations can reduce pain, lower inflammation, and affect the aging markers measured at the start and end of the trial.

The purpose of the study is to compare two different methods of blocking pain to see which one works better for patients after knee replacement surgery. One method involves blocking the genicular nerves, which are small nerves around the knee joint. The other method combines two types of blocks: one called the adductor canal block, which numbs nerves in a passage on the inner side of the thigh, and another called the IPACK block, which stands for infiltration between the popliteal artery and the capsule of the knee, targeting the back of the knee. The study will measure pain levels using a scale where patients rate their pain from zero to ten, with zero being no pain and ten being the worst pain imaginable.

During the study, patients will receive one of these two pain-blocking methods before their knee replacement surgery. After the surgery, the study team will check how much pain patients feel at different times, including right after surgery, at twelve hours, at twenty-four hours during their first physical therapy session, and at forty-eight hours. The study will also look at how much additional pain medicine patients need, how well they can move their knee, and their overall recovery quality. The treatment with the nerve blocks happens once, on the day of surgery, and the total amount of medication given will not exceed seventy milligrams of ropivacaine hydrochloride and three hundred fifty micrograms of epinephrine.

The purpose of this study is to find out if Montelukast is effective and safe for treating hand pain in people with erosive osteoarthritis of the hands. The researchers want to see if the medication can reduce pain intensity in the most affected hand after 24 weeks of treatment compared to placebo. Pain will be measured using a scale where participants mark how much pain they feel, ranging from no pain to the worst pain imaginable.

During the study, participants will take their assigned treatment for 24 weeks, which is about six months. Throughout this time, they will attend scheduled visits where doctors will check their pain levels and how well their hands are working. The study will compare the results between those taking Montelukast and those taking placebo to determine whether the medication makes a difference in reducing hand pain and improving the ability to use the hands for everyday tasks.

The treatment involves weekly injections of methotrexate under the skin, along with folic acid tablets to help manage potential side effects. Some participants will receive sodium chloride solution (salt water) injections instead of methotrexate. The study will last for 52 weeks, during which participants will receive regular medical check-ups to monitor their condition.

Throughout the study, doctors will track changes in the hand joints using special imaging techniques to see if the medication helps prevent further joint damage. This research is particularly important for people who continue to experience hand pain and difficulty with daily tasks despite trying other treatments for their arthritis.

The treatment involves applying clobetasol propionate directly to the skin of the hands. Participants in the study will follow a specific schedule where the medication is used twice a day for the first two weeks, followed by a period of using it once a day for the next two weeks. This approach is known as a tapering regimen, which means the amount or frequency of the medication is gradually reduced over time.

The purpose of the study is to determine whether the injection can reduce knee pain and improve function compared with the placebo. Participants will receive a single injection and then be asked to complete simple questionnaires about how their knee feels, how much it hurts, and how well they can perform daily activities. These questionnaires include the Western Ontario and McMaster Universities Arthritis Index (WOMAC), which scores pain, stiffness and functional ability on a scale from 0 to 100. Over the following months, researchers will also keep an eye on any adverse events or side effects and may take routine lab tests to check safety.

Participants will receive the treatment through a subcutaneous injection, which means the medicine is administered into the fatty layer of tissue just under the skin, using a pre-filled pen once a week. Throughout the study, changes in body weight and levels of pain in the knee will be observed. Other factors such as physical function, waist size, and certain blood measurements like cholesterol and blood pressure may also be monitored to understand the overall impact of the treatment.

Participants in the study will receive either the test medication or a placebo. The medication is administered through a subcutaneous injection, which means it is delivered into the fatty layer of tissue just under the skin, using a pre-filled pen once per week. During the study, changes in body weight, waist size, and various health measurements will be monitored. Additionally, the impact on knee pain, stiffness, and physical movement will be observed to see how the treatment affects daily function.

During the study, people will take either Orforglipron tablets or placebo tablets once each day for up to 72 weeks. The study will measure knee pain using a scoring system that asks questions about pain levels during different activities. Doctors will compare the changes in pain scores between people taking Orforglipron and those taking placebo to see if the medicine helps reduce knee pain. People in the study will need to be willing to stop taking certain pain medications throughout the entire study period.

The study is designed to help researchers understand whether this new medicine can help people who struggle with both excess weight and painful knee osteoarthritis. People joining the study should have tried to lose weight through diet at least once before without success. The study will look at how safe the medicine is and whether it works well for reducing the knee pain that comes with osteoarthritis in people who are overweight or have obesity.

The study is designed as a crossover trial, which means that participants will receive both the active medication and placebo at different times during the study. Each person will go through two treatment periods that last two weeks each. Before starting the treatment periods, there will be a run-in phase where participants keep a diary of their pain levels for seven days. During one treatment period, participants will take LTG-001 tablets, and during the other period, they will take placebo tablets. There will be a break of two weeks between the two treatment periods to make sure the effects of the first treatment have worn off before starting the second one. Throughout the study, participants will not be allowed to take other pain medications for osteoarthritis except for a rescue medication that is permitted by the study.

During the study, participants will be asked to rate their pain levels using different scales and questionnaires. These include questions about pain, stiffness, and how well they can perform daily activities. Participants will also be asked to complete a physical performance test and give their overall opinion about how the treatment is working. The study will monitor safety by checking for any unwanted effects, measuring vital signs like blood pressure and heart rate, doing blood tests, and taking blood samples to measure the levels of LTG-001 in the body. The study is expected to start enrolling participants in October 2025 and finish by August 2026.

The purpose of this research is to determine how well 4P-004 works in reducing knee pain and whether it is safe to use. During the study, participants will receive either 4P-004 or placebo injections. The treatment period lasts 12 weeks, during which participants will have their knee pain and overall condition regularly evaluated.

The medication will be administered as an injection solution, with a maximum daily dose of 2 milligrams. Throughout the study, participants will undergo various assessments to monitor their response to treatment, including evaluations of pain levels during daily activities and overall knee function. The study includes regular check-ups to monitor the participants’ health and safety.

The medication will be given as a single intramuscular injection, which means it is injected directly into a muscle. Some patients will receive the actual medication (Depo-Medrol), while others will receive sodium chloride solution as a placebo. The study will track how participants’ hand pain changes over time, particularly during the first four weeks after the injection.

Throughout the study, which lasts 48 weeks, researchers will monitor various aspects of the participants’ condition, including pain levels, hand function, and quality of life. They will also look at changes in joint structure and inflammation to better understand how the treatment works. This research aims to find out if this type of injection could be an effective treatment option for people with hand osteoarthritis who haven’t found sufficient relief from other pain medications.

Participants in the study will receive either the N-TEC implant or the standard treatment. The study will follow participants over a period of 24 months to observe changes in their condition. The main focus will be on improvements in knee function and pain, as measured by a specific scoring system. Additional assessments will include various health and activity scales, as well as imaging tests like MRI and X-rays, to monitor the progress of the treatment.

The trial aims to gather data on the effectiveness and safety of the N-TEC implant compared to the standard treatment. By the end of the study, researchers hope to have a clearer understanding of whether this new approach can offer better relief and improved quality of life for those suffering from patellofemoral osteoarthritis.

The purpose of the study is to evaluate how effective and safe the diclofenac gel AMZ001 is in reducing knee pain and symptoms associated with osteoarthritis. Participants in the study will apply the gel once daily for a period of up to six weeks. Throughout the study, participants will have regular check-ins to monitor changes in their knee pain and overall health. The main focus will be on changes in pain levels after two weeks of treatment, using a specific pain measurement tool called the WOMAC pain sub-score.

In addition to the main treatment, participants may also receive Panodil, a medication containing paracetamol, which is commonly used to relieve pain. The study aims to provide valuable information on how well the new gel works in comparison to existing treatments and to ensure its safety for people with knee osteoarthritis. Participants will be closely monitored to track any changes in their condition and to ensure their well-being throughout the trial.

The purpose of this research is to determine if the bovine-derived chondroitin sulfate works as effectively as the marine-derived version for treating pain and reduced function caused by knee osteoarthritis. The study examines how well both medications work in reducing knee pain and improving the ability to perform daily activities.

Participants in this study will take the assigned medication for 24 weeks (6 months). During this time, they will need to record their pain levels and ability to perform everyday activities. After the treatment period ends, there will be a 12-week follow-up period to continue monitoring the effects of the medication. Throughout the study, participants may be allowed to take paracetamol as a pain reliever if needed.

Participants in the study will receive either the LNA043 treatment or a placebo through injections into the knee. The study will last for up to five years, during which time the effects of the treatment on knee structure and function will be monitored. The main focus will be on changes in the knee’s structure, particularly in the central part of the knee joint, over a period of two years. Additionally, the study will look at changes in pain levels, physical function, and cartilage structure, as well as any side effects that may occur.

The study aims to provide valuable information on whether LNA043 can help improve the condition of the knee joint in people with osteoarthritis, potentially offering a new treatment option for managing this painful condition. Participants will be closely monitored throughout the study to ensure their safety and to gather comprehensive data on the treatment’s effects.

The purpose of the study is to determine if injecting this cell therapy into the temporomandibular joint can slow down the progression of the disease, help regenerate the joint surface, and improve the quality of life for patients. The study will involve collecting data on patients’ symptoms, clinical examinations, and imaging results to analyze the effectiveness of the treatment.

Participants in the study will receive either the cell therapy or a placebo through an intra-articular injection, which means the injection is given directly into the joint. The study will monitor the patients over a period to observe any changes in their condition and gather information that could be used in future clinical practice.

The purpose of the study is to evaluate how these different treatments affect thumb pain over a period of six months. Participants will receive their injections directly into the joint at the base of the thumb, guided by ultrasound to ensure accuracy. The study will also involve the use of a custom-made rigid splint, which is a supportive device designed to help manage the condition by keeping the thumb in a stable position.

Throughout the study, participants will be monitored to assess changes in their pain levels. The main goal is to determine which treatment option provides the most relief from pain associated with base-of-thumb osteoarthritis. This information will help in understanding the potential benefits of using Botox for this specific type of arthritis.

The purpose of this study is to assess how effective and safe KBP-336 is compared to a placebo. Participants in the study will receive either the new treatment or a placebo, and their progress will be monitored over a period of time. The study will look at changes in body weight and knee pain to determine the treatment’s effectiveness. Participants will be asked to follow a specific diet and exercise plan during the study.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The study aims to provide valuable information on whether KBP-336 can be a helpful addition to diet and exercise for managing weight and knee pain in people with obesity and osteoarthritis of the knee. The results of this study could lead to new treatment options for individuals facing these health challenges.

The purpose of the study is to evaluate how well PPV-06 works in reducing pain and improving physical function in people with knee osteoarthritis. Participants in the study will receive either the new treatment, paracetamol, or a placebo. The study will be conducted over a period of time, with regular check-ups to monitor the effects of the treatment on knee pain and function. Participants will be asked to stop using other pain medications, except for paracetamol, during the study.

The study will last for several months, with the main focus on changes in pain levels and physical abilities over time. Participants will undergo assessments, including imaging tests like MRI, to measure changes in the knee joint. The study aims to provide valuable information on the safety and effectiveness of PPV-06 for treating knee osteoarthritis.

Participants in the study will receive either the medication Rivaroxaban or a placebo, which looks like the medication but does not contain the active ingredient. The study aims to find out if the shorter duration of taking Rivaroxaban is as safe and effective as the longer duration. The trial will monitor for any signs of blood clots, as well as other health outcomes such as overall recovery, any serious side effects, and the need for additional hospital visits.

The study will follow participants for up to 90 days after they join to track their recovery and any health issues that arise. This research is important to potentially reduce the length of time patients need to take blood thinners after hip surgery, which could lead to fewer side effects and a quicker return to normal activities.

Participants in the study will receive either the treatment or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be adaptive, meaning it can adjust based on the results as it progresses. It is also randomized and double-blind, meaning neither the participants nor the researchers know who is receiving the treatment or the placebo, to ensure unbiased results. The study will take place over several weeks, with regular assessments to monitor pain levels and any side effects.

The main goal is to find the lowest dose of disodium clodronate that effectively reduces knee pain by at least 10 millimeters on a pain scale by the seventh week of the study. The safety and tolerability of the treatment will also be closely monitored, looking for any serious adverse events or signs of intolerance. This research will help determine the best dose to use in future studies and potentially offer a new treatment option for those suffering from painful knee osteoarthritis.

The purpose is to determine if the injection treatment works as well as the standard surgical treatment for managing wrist pain. The injection mixture contains 2 milliliters of processed fat tissue and 2 milliliters of concentrated platelets, both taken from the patient’s own body. This mixture is injected directly into the affected wrist joint.

During the study, patients will receive either the injection treatment or undergo the surgical denervation procedure. The effects of both treatments will be monitored for six months, with special attention paid to how well they reduce pain. The injection treatment, if proven effective, could offer patients a less invasive alternative to surgery for treating painful wrist arthritis.

The purpose of the study is to assess how well people tolerate this treatment over a period of six months. Participants will receive an injection directly into the affected joint. Throughout the study, the participants’ hand function and pain levels will be monitored at different intervals, specifically at one, three, and six months. This will help researchers understand how the treatment affects the joint and if it helps in reducing pain and improving hand function.

Additionally, the study will look at any side effects that might occur from the treatment. The researchers will also use imaging techniques like MRI and X-rays to see if there are any changes in the cartilage of the joint. This study aims to provide valuable information on the potential benefits and safety of using this cell therapy for treating rhizarthrosis.

The purpose of the study is to compare the effectiveness of the N-TEC implant with another treatment option. Participants in the study will be randomly assigned to receive either the N-TEC implant or a different treatment. The study will take place over a period of 24 months, during which participants will have regular check-ups to monitor their progress. These check-ups will include assessments of knee pain and function using various scales and questionnaires, such as the KOOS Pain scale, which measures knee pain and symptoms.

Throughout the study, participants will also undergo imaging tests like MRI to evaluate the condition of their knee cartilage and the success of the repair. The study aims to provide valuable information on whether the N-TEC implant can effectively reduce pain and improve knee function in people with patellofemoral osteoarthritis. Safety and any side effects will also be closely monitored to ensure the well-being of all participants.

Participants in the study will be randomly assigned to receive either Colchicine or a placebo. The study will last for a period of time, during which participants will take the medication daily. Throughout the study, researchers will monitor the participants to see if there is a difference in the number of knee or hip replacements needed between those taking Colchicine and those taking the placebo. Additionally, the study will observe changes in pain levels, physical function, and quality of life over the course of the trial.

The study will also look at other factors, such as the progression of osteoarthritis in other joints, the use of pain medication, and any new cardiovascular events that may occur. By the end of the study, researchers hope to gather valuable information on whether Colchicine can be an effective treatment option for reducing the need for joint replacement surgery in people with knee or hip osteoarthritis.

The purpose of the study is to compare how effective these treatments are in improving the symptoms of knee osteoarthritis. Participants will receive one of the treatments and will be monitored over time to see how their symptoms change. The study will look at various aspects such as pain levels, knee function, and any changes in the knee joint as seen on imaging tests like MRI. The study will also assess the quality of life of participants and any side effects related to the treatments.

Participants will be randomly assigned to receive one of the treatments, and the study will be conducted over a period of time to observe the effects. The treatments will be given through injections into the knee, and participants will have regular follow-up visits to monitor their progress. The study aims to provide valuable information on which treatment might be most beneficial for people with knee osteoarthritis.

The purpose of this study is to evaluate the safety and tolerability of the RTX-GRT7039 injections in individuals experiencing knee pain due to osteoarthritis. Participants in the study will receive these injections and will be monitored over a period of time to observe any side effects or changes in their condition. The study aims to gather information on how well the treatment is tolerated and whether it causes any adverse effects.

Throughout the study, participants will undergo various assessments, including imaging tests like X-ray and MRI scans, to check for any structural changes in the knee joint. Additionally, questionnaires will be used to evaluate changes in physical function, pain levels, and overall quality of life. The study is designed to provide valuable insights into the potential benefits and risks of using RTX-GRT7039 for managing knee pain associated with osteoarthritis.

Participants in the study will receive Tranexamic Acid through an injection into their vein at the start of the surgery. Some participants will also receive an injection of Tranexamic Acid directly into the hip joint at the end of the surgery, while others will receive an injection of a harmless saltwater solution, known as a placebo, instead. The main goal is to measure the total blood loss within 24 hours after the surgery.

The study will also look at the total blood loss on the morning of the second day after surgery. This research will help determine if the additional injection of Tranexamic Acid into the joint can provide extra benefits in reducing blood loss during hip replacement surgery for patients with Osteoarthritis.

The study will compare methotrexate with placebo in patients who experience hand pain and symptoms. Both methotrexate and placebo will be given as tablets that participants will take by mouth. The treatment will continue for 52 weeks, during which various aspects of hand function and pain levels will be monitored.

Throughout the study, researchers will examine changes in joint pain, hand function, and daily activities. They will use various methods to assess the effectiveness of the treatment, including imaging of the hands and measurements of grip strength. The study will also track any side effects that may occur during the treatment period.

The purpose of the study is to assess the safety and effectiveness of the PLX-PAD treatment for people with mild to moderate knee osteoarthritis. Participants will receive injections and be monitored over time to see how their symptoms change. The study will include regular check-ups and assessments, such as imaging tests like MRI to look at the knee joint, and questionnaires to evaluate pain and quality of life. The study will last several years, with follow-up visits to track long-term effects.

In addition to the main treatment, the study will also involve the use of cetirizine dihydrochloride, a medication commonly used for allergies, to help manage any potential allergic reactions during the trial. Participants will be closely monitored for any side effects or changes in their condition throughout the study. The goal is to gather information that could lead to new treatment options for knee osteoarthritis in the future.

The purpose of the study is to evaluate the safety and tolerability of Allocetra-OTS when injected directly into the knee joint. The study will compare the effects of this treatment to a placebo, which is a substance with no active ingredients. Participants will receive injections in their knee and will be monitored over several months to see how their knee pain and function change over time. The study will also look at any side effects that may occur during the treatment period.

Participants in the study will be randomly assigned to receive either the Allocetra-OTS treatment or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with follow-up visits to assess the participants’ progress and any changes in their knee condition.

The purpose of the study is to compare the effects of Metformin with a placebo, which is a substance that looks like the medication but contains no active ingredients. Participants in the study will be randomly assigned to receive either Metformin or the placebo. The study will last for 16 weeks, during which participants will take the medication or placebo and have their finger joint pain assessed. The main goal is to see if Metformin can help reduce pain in the hand joints compared to the placebo.

Throughout the study, participants will have their pain levels measured using a simple scale to track any changes. This will help researchers understand if Metformin can be an effective treatment for hand osteoarthritis. The study aims to provide valuable information on whether Metformin can offer relief for those suffering from this condition.

Participants in the study will be randomly assigned to receive either QUC398 or a placebo. The study is designed to be “blinded,” meaning that neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will last for about a year, with regular check-ups to monitor the participants’ progress and any changes in their knee pain.

Throughout the study, participants will have their knee pain assessed using a scale called the Knee Injury and Osteoarthritis Outcome Score (KOOS). This will help determine if there is any improvement in pain levels. Additionally, the study will look at changes in the knee’s cartilage volume using MRI scans. Safety and any side effects will also be closely monitored to ensure the well-being of all participants. The goal is to gather information on the effectiveness and safety of QUC398 as a potential treatment for knee osteoarthritis.

The purpose of the study is to evaluate how the treatment affects pain in the knee. Participants will be randomly assigned to receive either the APPA capsules, Panodil, or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not influenced by expectations. The study will last for a period of 12 weeks, during which participants will take the assigned treatment and attend regular check-ups to monitor their progress.

Throughout the study, participants will be asked to report on their knee pain and any changes they experience. The main focus will be on changes in pain levels, but other aspects such as knee function and overall quality of life will also be assessed. The goal is to determine if the combination of apocynin and paeonol can provide relief from the symptoms of knee osteoarthritis and improve the daily lives of those affected by this condition.

The purpose of the study is to determine how well the capsaicin patch works in relieving pain in patients with digital osteoarthritis, especially those who experience a type of pain known as neuropathic pain, which is caused by nerve damage. Participants in the study will receive either the high-dose or low-dose patch, and their pain levels will be monitored over a period of eight weeks. The study aims to see if the higher dose of capsaicin provides better pain relief compared to the lower dose.

Throughout the study, participants will have their finger pain assessed using a visual scale that measures pain intensity. This will help researchers understand the effectiveness of the capsaicin treatment in managing pain associated with digital osteoarthritis. The study is designed to provide valuable information on whether the capsaicin patch can be a beneficial treatment option for those suffering from this painful condition.

The purpose of the study is to assess the effectiveness of GAE in reducing knee pain over a period of three months. Participants will receive either the GAE treatment or the sham procedure, and their pain levels will be monitored and compared. The study will also look at other aspects of knee health and overall well-being over a longer period, up to 12 months. This will help researchers understand if the treatment has lasting benefits and how it affects the quality of life for people with knee osteoarthritis.

Throughout the study, participants will have regular check-ups to monitor their progress and any changes in their condition. The study aims to provide valuable information on whether this new treatment can offer relief for those suffering from knee osteoarthritis, potentially leading to new options for managing this common and often painful condition.

The purpose of the study is to determine how effective DFV890 is in relieving knee pain in people with knee osteoarthritis. Participants in the study will take either DFV890 or a placebo for a period of 12 weeks. During this time, researchers will monitor changes in knee pain and other symptoms using a specific scoring system. The study will also look at the safety and tolerability of DFV890, which means checking for any side effects or adverse reactions.

Throughout the study, participants will have regular check-ups to assess their knee condition and overall health. This will include various tests and measurements, such as blood tests and imaging techniques like MRI (Magnetic Resonance Imaging), to evaluate the level of inflammation in the knee. The study aims to provide valuable information on whether DFV890 can be a beneficial treatment option for those suffering from knee osteoarthritis.